900000000000526001: REPLACED BY association reference set (foundation metadata concept)

SNOMED CT Concept\SNOMED CT Model Component\Foundation metadata concept (foundation metadata concept)\Reference set\Association type\Historical association reference set (foundation metadata concept)\REPLACED BY association reference set (foundation metadata concept)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT model component module (core metadata concept)

Descriptions:

Id Description Lang Type Status Case? Module

900000000001156010 REPLACED BY association reference set (foundation metadata concept) en Fully specified name Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)

900000000001157018 REPLACED BY association reference set en Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
REPLACED BY association reference set (foundation metadata concept)	Is a	Historical association reference set (foundation metadata concept)	true	Inferred relationship	Some

Members	targetComponentId
Drug cream, 0,01%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,02%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,025%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,05%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,1%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,25%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 0,5%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 1%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug cream, 2,5%	A semi-solid dose form of homogeneous appearance consisting of a lipophilic phase and an aqueous phase, one of which is finely dispersed in the other. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic.
Drug dependence	The inability to regulate the use of a specified substance due to repeated or continuous use. Key features include a strong internal drive to use the substance, impaired control over use, prioritizing use over other activities, and continued use despite harm or negative consequences. This often comes with urges or cravings. Physiological dependence may also occur, marked by tolerance, withdrawal symptoms, or use of the substance to prevent withdrawal. These features typically appear over 12 months but can be diagnosed if use is continuous for at least 3 months.
Drug dependence - unspecified whether during pregnancy or the puerperium	Substance dependence during pregnancy, childbirth and/or puerperium (disorder)
Drug dependence NOS	The inability to regulate the use of a specified substance due to repeated or continuous use. Key features include a strong internal drive to use the substance, impaired control over use, prioritizing use over other activities, and continued use despite harm or negative consequences. This often comes with urges or cravings. Physiological dependence may also occur, marked by tolerance, withdrawal symptoms, or use of the substance to prevent withdrawal. These features typically appear over 12 months but can be diagnosed if use is continuous for at least 3 months.
Drug dependence NOS	The inability to regulate the use of a specified substance due to repeated or continuous use. Key features include a strong internal drive to use the substance, impaired control over use, prioritizing use over other activities, and continued use despite harm or negative consequences. This often comes with urges or cravings. Physiological dependence may also occur, marked by tolerance, withdrawal symptoms, or use of the substance to prevent withdrawal. These features typically appear over 12 months but can be diagnosed if use is continuous for at least 3 months.
Drug dependence during childbirth, puerperium (& pregnancy)	Substance dependence during pregnancy, childbirth and/or puerperium (disorder)
Drug dependence during pregnancy, childbirth and the puerperium	Substance dependence during pregnancy, childbirth and/or puerperium (disorder)
Drug dependence during pregnancy, childbirth or the puerperium NOS	Substance dependence during pregnancy, childbirth and/or puerperium (disorder)
Drug dependence in childbirth	Substance dependence in childbirth
Drug dependence in mother complicating pregnancy, childbirth AND/OR puerperium	Substance dependence in mother complicating pregnancy, childbirth and/or puerperium (disorder)
Drug dependence in remission	Substance dependence in remission
Drug dependence, continuous	Substance dependence, continuous
Drug dependence, episodic	Substance dependence, episodic (disorder)
Drug for supraventricular arrhythmia	Antiarrhythmic agent (substance)
Drug for ventricular arrhythmia	Antiarrhythmic agent (substance)
Drug gel, 0,05%	A semi-solid dose form consisting of a hydrophilic gel.
Drug gel, 0,1%	A semi-solid dose form consisting of a hydrophilic gel.
Drug gel, 0,25%	A semi-solid dose form consisting of a hydrophilic gel.
Drug groups and agents primarily acting on skin adverse reaction	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug groups primarily affecting autonomic nervous system adverse reaction	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug groups primarily affecting cardiovascular system adverse reaction	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug groups primarily affecting central nervous system adverse reaction	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug groups primarily affecting gastrointestinal system adverse reaction	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug groups primarily affecting musculoskeletal system adverse reaction	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug groups primarily affecting respiratory system adverse reaction	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug groups primarily affecting the autonomic nervous system	Product containing autonomic agent (product)
Drug hypersensitivity (& [NOS])	Propensity to adverse reactions to drug
Drug hypersensitivity	Propensity to adverse reactions to drug
Drug hypersensitivity NOS	Propensity to adverse reactions to drug
Drug induced rash (& ingestion dermatitis)	Dermatitis caused by substance taken via oral route (disorder)
Drug level in urine specimen above therapeutic range	Urine substance level above reference range (finding)
Drug ointment, 0,025%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 0,05%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 0,1%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 0,2%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 0,25%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 1%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug ointment, 2,5%	A semi-solid dose form consisting of a single-phase in which solids or liquids may be dissolved or dispersed in the base, which may be hydrophilic, hydrophobic or water-emulsifying.
Drug reaction - CNS drug	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug reaction - CNS drug	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug reaction - CNS drug NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug reaction - CNS drug NOS	All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
Drug reaction to analgesic NOS	Analgesic adverse reaction
Drug reaction to analgesic NOS	Analgesic adverse reaction
Drug specific allergen extract	Pharmaceutical / biologic product (product)
Drug therapy NOS	Drug therapy (procedure)
Drug therapy NOS	Drug therapy (procedure)
Drug therapy status	Drug therapy with explicit context
Drug withdrawal	Substance withdrawal
Drug withdrawal seizure	Seizure co-occurrent and due to substance withdrawal
Drug withdrawal syndrome	Substance withdrawal
Drug withdrawal syndrome	Substance withdrawal
Drug, medicament or biological substance	A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.
Drug, medicament, or biological substance in urine above reference range	Urine substance level above reference range (finding)
Drug-induced impotence	Erectile dysfunction caused by drug
Drug-induced nephrogenic diabetes insipidus	Acquired vasopressin resistance
Drug-related disorder	Disease
Drugs for guinea worms [no drugs here]	Anthelmintic
Drugs for hookworms	Anthelmintic
Drugs for the control of epilepsy	Anticonvulsant
Drugs for threadworms	Anthelmintic
Drugs for trichomonacides	Antiprotozoal
Drugs in urine abnormal [D]	Substance in urine detected by screening method (finding)
Drugs used in hyperuricemia	Uricosuric agent (substance)
Drugs used in infections	Anti-infective agent (substance)
Drugs used in malignant disease and for immunosuppression	Immunosuppressant (substance)
Drugs used in megaloblastic anemias	Haematinic
Drusen	Hyaline body
Duct contrast radiography NOS	Plain X-ray of bile duct with contrast
Duct contrast radiography NOS	Plain X-ray of bile duct with contrast
Duct ectasia	Dilatation
Ductal carcinoma in situ - category	Non-infiltrating intraductal carcinoma
Dukes-Filatow disease	Rubeola scarlatinosa
Dundee cardiovascular risk score	Dundee Coronary Risk Disk (assessment scale)
Duodenal ulcer NOS	Ulcer of duodenum (disorder)
Duodenal ulcer NOS	Ulcer of duodenum (disorder)
Duodenitis caused by ingestible alcohol	Duodenitis caused by ethanol (disorder)
Duodenoscopy: [diagnostic NOS] or [NEC]	Duodenoscopy
Duplicate concept	A component has been made inactive because it duplicates another component of the same type. E.g. A description that duplicates another description or a concept that duplicates another concept.
Duplicate report	Duplicate report (record artifact)
Dupuytren contracture repaired by division of palmar aponeurosis	Dupuytren contracture corrected by division of palmar aponeurosis
Dupuytren's disease of finger(s), nodules with no contracture	Dupuytren's disease of finger
Dupuytren's disease of palm, nodules with no contracture	Dupuytren's disease of palm
Dwarfism NEC	Short stature disorder
Dwarfism NEC NOS	Short stature disorder
Dwarfism, NEC	Short stature disorder
Dyclonine hydrochloride 1% topical solution (product)	Product containing precisely dyclonine hydrochloride 10 milligram/1 milliliter conventional release cutaneous solution (clinical drug)
Dynamite, device	Dynamite stick (physical object)
Dyphylline + guaifenesin 100mg/100mg elixir	Product containing precisely diprophylline 6.67 milligram/1 milliliter and guaifenesin 6.67 milligram/1 milliliter conventional release oral solution (clinical drug)
Dyphylline 160mg/15ml elixir	Diprophylline 10.7 mg/mL oral solution
Dyskinesia of esophagus	Diffuse spasm of esophagus
Dysmnesic seizure	An epileptic seizure originating within networks limited to one hemisphere, initially manifesting with impairment of memory, regardless of whether aware or with impaired awareness. This can manifest as déjà vu or jamais vu.
Dyssegmental dysplasia with glaucoma syndrome	Rolland-Debuqois syndrome

Start Previous Page 57 of 235 Next End

Reference Sets

Reference set descriptor

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
900000000001156010	REPLACED BY association reference set (foundation metadata concept)	en	Fully specified name	Active	Entire term case sensitive (core metadata concept)	SNOMED CT model component module (core metadata concept)
900000000001157018	REPLACED BY association reference set	en	Synonym (core metadata concept)	Active	Entire term case sensitive (core metadata concept)	SNOMED CT model component module (core metadata concept)